Holland Lab

It was a real pleasure to host @medbioinorgchem.bsky.social at @chem.uzh.ch Thank you for coming, and we’ll see you soon!

Huge congratulations to our Master’s student, Tiago, for successfully defending his thesis! His work, “Synthetic Strategies Towards fac-{ReO₃}⁺ and fac-{⁹⁹ᵐTcO₃}⁺ containing Radiotracers”, represents an exciting advancement in our lab’s research. Well done! 🌟

We are pleased to introduce our PhD student, Jonas Genz. You can find his recent paper at the following link 🙌
doi.org/10.1039/D4SC...

@chemicalscience.rsc.org #Radiochemistry #Research

Big thank you to @gtonon.bsky.social for his work over the last six months. All the best for the rest of your PhD!

A big congratulations to our Master’s student, Dominik, on successfully defending his thesis today! His work, ‘Towards Radionuclide Incorporation into Lacunary Polyoxometalates’, marks an exciting step forward in our lab’s research. Well done!🌟
#Defence #Thesis #Radiochemistry #Polyoxometalates

Big thank you to the organisers of ICBIC! My group members had an awesome time, made even better with Samy winning a poster prize! 🏆

Those attending ICBIC - please be sure to check out the posters of my group members #509-511. They’d love the chance to talk about their cool results!

Exciting News!🎉

@kanishkasikligar.bsky.social & I are co-chairing the Metals in Medicine GRS 2026-Transforming Medicine with Inorganic Chemistry! 🧪 🔬💊

A must for early-career researchers to explore cutting-edge science & network. Join us in June 2026! 👇
🔗 lnkd.in/e7JJYY3R

CHEMCUP CHAMPS! 🏆

HollandLab kicked, spiked, and laughed our way to victory at this year’s ChemCup! First win ever and definitely not the last 😎⚽️🏐

Big thanks to the orga team and @michaljuricek.bsky.social for making it all happen!
#ChemCup #HollandLab #Teamwin @chem-uzh-ch.bsky.social

Awesome to get support from the UZH postdoc grant to work on developing my own ideas with @hollandlab.bsky.social ! An exciting project too, if I do say so myself 😅

Congratulations Simon and team!

Congratulation to the two successful candidates of the
@chem-uzh-ch.bsky.social on receiving an UZH Postdoc Grant 👏👏

We are pleased to begin our laboratory introductions with the leader of our research group, Professor Dr. Jason P. Holland.

Stay tuned to meet the brilliant minds behind our research! 💡

#Radiochemistry #MolecularImaging #UZH #MeetTheTeam #Chemistry

Our first work with 161Tb. Great stuff from @pacieslik.bsky.social and colleagues. In collaboration with Nick van der Meulen and his team at the PSI.
@erc.europa.eu
@chem-uzh-ch.bsky.social

Congratulations! Super cool that our collaborative Smartdrugs team is already publishing primary science together! Sure my team will get in on the act in the coming year!

Design of porous self-assembled homoleptic and heteroleptic Pd2+ cages incorporating silicon-based fluoride acceptors: the way towards nuclear imaging applications Supramolecular self-assembly is a promising tool to develop multifunctional theranostic agents and has recently entered the field of radiochemistry. In this work, lantern-shaped [Pd2L4]4+ metallacages...

Check out our latest study on Pd-cages for dual-modality imaging including cool MS analysis and fancy in ovo PET imaging, doi.org/10.1039/D5QI...
Congrats to Marike Drexler, Luisa Ronga, Ioannis Kanavos, @gmalcantar.bsky.social Daniela Kraus @timwitney.bsky.social! EIC Pathfinder #SMARTdrugs

Light-Induced Synthesis and Radiotheranostic Treatment of Gastric Cancer with 161Tb-Labeled Monoclonal Antibodies Radiolabeled monoclonal antibodies (mAbs) form a major branch of nuclear medicine and are used in the development of tracers for both diagnostic imaging and molecularly targeted radio(immuno)therapy (RIT). Since treatment options for many types of late-stage cancers are limited and these diseases become refractory to classic chemotherapy, new tools are required to improve patient outcomes. The high tumor uptake and specificity of mAbs, coupled with increased therapeutic range of energetic β–-emitting radionuclides, offers a potential solution to overcome traditional problems associated with poor tissue penetration of antibody-drug conjugates, chemotherapeutic resistance, and off-target accumulation, which can lead to adverse responses. The challenge is to develop efficient and reliable chemical methods that provide simultaneous selectivity and high stabilization of the radiometal via complexation chemistry, with rapid access to new bioconjugate bonds on protein that avoid the loss of bioactivity. Here, we designed a new octadentate bispidine-chelating system, functionalized with a light-responsive tetrazole unit, and demonstrated the chemoselective derivatization of sulfhydryl groups introduced on the protein surface. High radiolabeling and bioconjugation yields of 161Tb-onartuzumab─an engineered mAb fragment targeting the human hepatocyte growth-factor receptor (c-MET; a characteristic biomarker found in clinical samples of several diseases, including gastric adenocarcinomas)─were obtained under ambient conditions after 5 min of light-induced coupling. Comprehensive biochemical and animal experiments including cellular binding assays, noninvasive γ-ray imaging, biodistribution studies, and pharmacokinetic measurements established the viability of using 161Tb-onartuzumab to target c-MET expression in vivo. Subsequent RIT studies in MKN-45 xenograft models demonstrated that the 161Tb-onartuzumab radiotracer formed by photoradiosynthesis permitted low-dose therapy studies that led to efficient targeting and treatment of tumor models. Collectively, the new complexation and chemoselective photoconjugation chemistries overcome some of the limitations in traditional labeling approaches. Photoradiosynthesis represents an excellent platform for building future antibody-based radiotracers for applications in diagnostic and therapeutic medicine.

Happy to share that my second paper from the @hollandlab.bsky.social is online now! We have discovered a new bioconjugation strategy and have tested it in terms of Radioimmunotherapy with Tb-161!

Thanks to all authors!

doi.org/10.1021/jacs...

Biopharma dives into tumor-seeking radioactive drugs Nature Biotechnology - Big pharma and investors are piling into the precision radiation space as the next generation of increasingly potent targeted α-particle therapies promises to destroy...

Extremely honoured to have our work on supramolecular radiopharmaceuticals highlighted in the latest news in Nature Biotechnology!!! Thank you to the EIC Pathfinder SMARTdrugs @timwitney.bsky.social @hollandlab.bsky.social Alex Poot (UMCU) @cicbiogune.bsky.social Jordi Llop ! rdcu.be/emCW6

We’re hiring. Postdoctoral and PhD positions available in Medicinal Radiochemistry.

Must have high level of skills and experience in synthetic chemistry, with knowledge of radiochemistry, cellular studies, in vivo imaging desirable.

@erc.europa.eu
@snsf-ch.bsky.social
@chemuzhch.bsky.social

Thanks for speaking up. We can only hope it makes a difference.

www.bmj.com/content/389/...

The UK politicians continuous trumpet on about how great the NHS is but the truth is that patient experiences don’t lie. This is a backward system with too much money spent on management instead of frontline care, archaic rules, and substandard practice. So sad :-(

📢 Two new open positions!

Join the radiochemistry team of Prof. @annajunker83.bsky.social!

🗓️Deadline: 31 May 2025

📚PhD
🔗 jobs.medizin.uni-tuebingen.de/Job/6149/PhD...

🧪Post-doc
🔗 jobs.medizin.uni-tuebingen.de/Job/6163/Pos...

Looking forward to new additions to our growing team!

#Job #Vacancy

New paper out by Cesare Berton and Jason Holland @chem-uzh-ch.bsky.social featured on the cover of ChemComm pubs.rsc.org/en/Content/A...

The new paper published by the Holland group demonstrated that photoradiosynthesis can be employed
to develop a variety of rhenium based radioimmunoconjugates for future applications in tumor targeted
radioimmunotherapy.
pubs.rsc.org/en/content/a...

The HollandLab has migrated to BlueSky. ... more information to follow.